Everything below concerns LC-MS/MS. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-06-07. Numbers and descriptions here follow the published literature rather than marketing material.
Preclinical research reported that GW501516 increased running endurance in mice and improved lipid profiles in some animal species. Early human trials explored effects on high-density lipoprotein cholesterol, triglycerides, and glucose handling, but the program was discontinued. Published human data are sparse and do not establish efficacy for any condition. Studies also examined PPAR delta in cancer biology, with conflicting findings across models. The relationship between receptor activation, tissue context, and disease risk remains an active area of investigation.
Anti-doping laboratories identify GW501516 and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is the usual matrix, and detection can occur after the parent compound has cleared from blood. The exact detection window depends on dose, formulation, individual metabolism, and assay sensitivity. Because the compound is prohibited at all times, athletes are subject to testing in and out of competition. Analytical methods continue to improve as new metabolites and designer analogs are characterized.
GW501516 acts as a ligand for PPAR delta, a nuclear receptor that regulates transcription of genes involved in fatty acid oxidation and energy use. Activation of this receptor in skeletal muscle shifts metabolism toward fat burning in animal models. The compound does not burn fat directly; it changes gene expression over hours to days. Researchers study it to understand metabolic flexibility and exercise adaptation. Effects observed in rodents are not automatically expected in humans.
GW501516 acts as an agonist at the peroxisome proliferator-activated receptor delta, a nuclear receptor that regulates gene expression. Activation shifts transcription toward genes involved in fatty acid uptake, oxidation, and energy expenditure. The compound does not bind the androgen receptor and therefore differs from anabolic steroids and SARMs. In rodent models, this metabolic shift has been linked to increased running endurance and reduced fat accumulation. The exact downstream pathways in humans remain incompletely characterized.
Early clinical research explored GW501516 for lipid disorders, obesity, and diabetes. Some short-term human studies reported changes in HDL cholesterol, LDL cholesterol, and triglycerides. The development program was discontinued after rodent studies showed dose-dependent tumor formation in multiple tissues, including liver, bladder, stomach, and skin. These findings raised concerns about long-term cancer risk in humans. Because human exposure data are limited, the clinical significance of the rodent tumors remains uncertain.
Literature on cardarine often separates receptor pharmacology from toxicology. Mechanistic papers describe PPARδ activation and gene expression changes, while safety assessments focus on carcinogenicity and species differences. Questions remain about whether rodent tumors arise through PPARδ-dependent or off-target mechanisms. Another open area is how human metabolism and exposure compare with those in animal studies. Analytical methods such as liquid chromatography–mass spectrometry are used to confirm identity in biological and product samples.
| Property | Value | Notes |
|---|---|---|
| Molecular target | PPAR delta (NR1C2) | Ligand-activated nuclear receptor. |
| Primary tissues studied | Skeletal muscle, liver, adipose | Effects on fatty acid oxidation and energy use. |
| Typical detection matrix | Urine | Used in anti-doping analysis. |
| Common analytical method | LC-MS/MS | Detects parent compound and metabolites. |
| Sport regulatory class | Prohibited at all times | Listed as a metabolic modulator by WADA. |
Cardarine is a common name for GW501516, also GW-1516, a synthetic compound developed as a peroxisome proliferator-activated receptor delta (PPARδ) agonist. It belongs to a class of agents that modulate gene transcription related to lipid and energy metabolism. The compound was studied in preclinical and early clinical research for metabolic and cardiovascular conditions, but it did not progress to approved therapeutic use. Its name appears in fitness and sports contexts despite not being approved as a drug.
PPARδ is a nuclear receptor that influences transcription of genes involved in fatty acid oxidation, lipid transport, and energy homeostasis. GW501516 binds and activates this receptor with high selectivity relative to PPARα and PPARγ in laboratory assays. Activation alters expression of target genes in skeletal muscle, liver, and adipose tissue in animal models. The exact clinical consequences of these changes in humans remain incompletely characterized, and observed effects in animals do not establish therapeutic benefit or safety.
Published studies have examined GW501516 in animal models of obesity, insulin resistance, and exercise endurance. Early human trials reportedly ended, and development was discontinued after preclinical findings raised concerns about cancer in some rodent studies. Regulatory agencies have not approved cardarine for any medical use. Its availability through non-pharmaceutical channels raises questions about identity, purity, and legal status that are separate from its laboratory pharmacology. Those questions are often addressed through analytical testing rather than assumptions about product labels.
Cardarine is not approved for human therapeutic use in any major jurisdiction. It appears on the World Anti-Doping Agency Prohibited List as a PPARδ agonist within the hormone and metabolic modulators category. Sports organizations test for it because it has been detected in athlete samples and seized products. Regulatory actions against marketed research chemical versions have occurred in several countries, though enforcement varies. Availability through unregulated channels complicates oversight.
Analytical laboratories typically identify cardarine and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is a common matrix in anti-doping testing, while blood and tissue may be used in research settings. Detection windows depend on the assay, the sample matrix, and the compound's metabolism. Because cardarine is extensively metabolized, laboratories often target specific metabolites to improve sensitivity and confirmation. Reference standards are required for reliable quantification. Method validation includes checks for selectivity, linearity, and carryover.
GW501516 binds and activates PPARδ, a nuclear receptor that influences transcription of genes involved in fatty acid oxidation and energy use. Activation shifts some metabolic pathways in preclinical models, which is why the compound has been studied for lipid disorders and exercise-related endpoints. The exact downstream effects in humans are incompletely mapped. PPARδ is expressed in many tissues, including skeletal muscle, liver, and adipose tissue, so broad activation may have varied consequences. Researchers continue to examine how selective or partial activation might alter the balance between benefits and risks.
Published human data are sparse and mostly come from early-phase trials. Those studies examined short-term changes in lipids, glucose, and exercise capacity, but they were not large enough to establish efficacy or long-term safety. Some animal experiments reported increased running endurance, yet such findings do not prove a performance benefit in people. Anti-doping laboratories detect GW501516 and its metabolites in urine or blood using liquid chromatography-tandem mass spectrometry. Detection windows depend on dose, sample type, and individual metabolism. The method is sensitive enough to identify trace residues in tested samples.
On 19 December, the National Guard stated that Syrian government forces in Rimat Hazim and Al-Mazra'a launched attacks towards Al-Majdal with drones and mortar fire, injuring two civilians, in addition to an infiltration by Syrian government forces on the northwest axis, resulting in four wounded. The National Guard accused Tareq al-Shoufi of "collaborating with Sharaa, and [he] went into hiding", while al-Hijri was "accused of kidnapping and his son of dealings with regional drug-smuggling networks, including Hezbollah." On 23 December, the National Guard stated that the Syrian government forces had “continued their attacks against al-Jabal and the surrounding areas”, using mortar fire, heavy machine guns, and drones. The city of Attil was attacked with mortar fire from Rimat Hazem and Tel Hadid, causing two deaths and eight injuries. There was also an attack on the civilian prison of Suwayda and transport directorate using heavy machine guns and mortar fire. On 24 December, clashes occurred between the National Guard and the Syrian government forces on the Ara-Khirbet Samar axis in the rural area of Suwayda and on the al-Majdal-al-Mazra'a axis, using 23mm heavy machine guns. That same day, the Royal Jordanian Air Force launched attacks on Suwayda that targeted “a series of factories and workshops that drug and arms traffickers use as bases to launch their illegal operations into Jordanian territory", It also attacked seven sites under the control of the National Guard, including a suspected weapons depot in Al Kafr, belonging to the Suwayda Military Council.
Department of Defense in 2012, when the devices were not yet commercially available and therefore did not require FDA approval. FDA inspection reports from 2014 and 2015 stated that its containers for blood collection were "not validated under actual or simulated use conditions" and "were not reviewed and not approved by designated individual(s) prior to issuance". In 2015, an FDA inspection resulted in multiple observed violations of FDA Title 21 Regulations. It was eventually revealed that the FDA had classified Theranos's device, called a nanotainer, as a Class II medical device, meaning that Theranos would need to use special labels, meet certain performance standards and perform post-market surveillance of the device. Theranos asserted that the nanotainer was a Class I medical device and therefore not subject to any regulatory requirements. After the 2015 inspection, Theranos announced that it would voluntarily suspend its tests apart from the FDA-approved herpes simplex virus (HSV-1) test. The Arizona Department of Health Services reported issues with the company's Scottsdale lab meeting regulations in September 2015. The reports were revealed in the Arizona Republic in November 2015. In January 2016, the Centers for Medicare and Medicaid Services (CMS) sent a letter to Theranos based on a 2015 inspection of its Newark, California lab, reporting that the facility caused "immediate jeopardy to patient health and safety" due to a test to determine the correct dose of the blood-thinning drug warfarin.
=== Deconvolution of libraries cleaved from the solid support === If the synthesized molecules of a combinatorial library are cleaved from the solid support, a soluble mixture forms. In such solution, millions of different compounds may be found. When this synthetic method was developed, it first seemed impossible to identify the molecules, and to find molecules with useful properties. Strategies for identification of the useful components have been developed, however, to solve this problem. All these strategies are based on synthesis and testing of partial libraries. An early iterative strategy was devised by Furka in 1982. The method was later independently published by Erb et al. under the name "Recursive deconvolution"
Sources: en.wikipedia.org
== Development == The game was originally created and released by Daniel Fearon. At the time, Fearon was one of the maintainers of the Half-Life fan website Atomic Half-Life, created in anticipation of the game's release. Fearon was sent a copy of Half-Life by Valve prior to its official release, and while playing it, he toyed with the game's code, figuring out how to spawn enemy creatures in multiplayer maps. Fearon's work had initially been done before Valve released the software development kit for Half-Life, requiring him to craft the modification atop the existing Half-Life distribution and to work with multiplayer over slower internet connections, such as phone-line modems. Fearon initially developed a single map that could be played cooperatively, and later a second version with two maps. The first public version of Sven Co-op was released on January 19, 1999, about 3 months after the release of Half-Life. He used the name Sven Co-op to reflect his online handle, "Sven Viking". Contrary to the common belief that Sven Co-op was developed to play through Half-Life cooperatively, Fearon had wanted to create a means for players to engage in cooperative experiences together, often just spawning in large number of enemies for them to dispatch together on a single map. This drew a number of amateur level developers to craft mission-based maps for the mod, where players would be required to go to different areas on the map based on success or failure of a given objective.
==== Shelf fluid ==== The amount of heat energy needed at times of the primary and secondary drying phase is regulated by an external heat exchanger. Usually, silicone oil is circulated around the system with a pump.
There are several Akabori amino acid reactions, which are named after Shirō Akabori (Japanese: 赤堀 四郎) (1900–1992), a Japanese chemist. In the first reaction, an α-amino acid is oxidised and undergoes decarboxylation to give an aldehyde at the former α position by heating with oxygen in the presence of a reducing sugar. This reaction is useful for preparing dichlorophthalimido derivatives of peptides for mass spectral analysis.
Sources: en.wikipedia.org
==== Chemical shielding ==== It might appear from the above that all nuclei of the same nuclide (and hence the same γ) would resonate at exactly the same frequency but this is not the case. The most important perturbation of the NMR frequency for applications of NMR is the "shielding" effect of the shells of electrons surrounding the nucleus. Electrons, similar to the nucleus, are also charged and rotate with a spin to produce a magnetic field opposite to the applied magnetic field. In general, this electronic shielding reduces the magnetic field at the nucleus (which is what determines the NMR frequency). As a result, the frequency required to achieve resonance is also reduced. This shift in the NMR frequency due to the electronic molecular orbital coupling to the external magnetic field is called chemical shift, and it explains why NMR is able to probe the chemical structure of molecules, which depends on the electron density distribution in the corresponding molecular orbitals. If a nucleus in a specific chemical group is shielded to a higher degree by a higher electron density of its surrounding molecular orbitals, then its NMR frequency will be shifted "upfield" (that is, a lower chemical shift), whereas if it is less shielded by such surrounding electron density, then its NMR frequency will be shifted "downfield" (that is, a higher chemical shift). Unless the local symmetry of such molecular orbitals is very high (leading to "isotropic" shift), the shielding effect will depend on the orientation of the molecule with respect to the external field (B0).
While statins are generally well-tolerated, severe adverse effects such as hepatotoxicity and myotoxicity may occur in rarity. Statin-induced hepatotoxicity can cause autoimmune hepatitis and an elevation in serum levels of hepatic enzymes such as alanine aminotransferase, impairing liver function. Myotoxicity is commonly presented with statin-associated muscle symptoms (SAMS), which include myalgia and myositis. In rare cases, they may progress into rhabdomyolysis, a condition manifested by muscle necrosis and myoglobinuria due to heightened creatine kinase levels. Another consequence of taking statins is the risk of developing new-onset diabetes, which is more prominent in individuals with high TG levels and body mass index (BMI). However, the risk is far outweighed by the benefits from statin therapy for the reduction in cardiovascular outcomes. Given the potential of statins to exacerbate liver and muscle abnormalities, contraindications of statins include decompensated liver cirrhosis, acute liver failure, unexplained and persistent elevations of serum transaminases, and myopathy. Moreover, statins are not recommended in pregnancy as they may cause foetal harm because of their mechanism of action. Metabolised by the Cytochrome P450 (CYP450) enzyme, a major metabolic enzyme, simvastatin and lovastatin may accumulate in blood when administered with CYP450 inhibitors. Some of these inhibitors are azole antifungals, macrolides, CCBs, ticagrelor (antiplatelet) and grapefruit juice.
A person was killed and 19 others, including two military personnel were injured in a suicide VBIED attack by Hafiz Gul Bahadur Group on the Bannu–Miranshah road. Pakistani Police forces neutralized two IEDs with 140+ kilograms and an 8kg explosive device in Bannu District. On the same day, some tribal elders and former military personnel in Afghanistan's border provinces said that the Taliban had asked them to support its conflict with Pakistan and to organize public protests against the country. According to them, as tensions between the Taliban and Pakistan continued, Taliban officials in Khost, Paktika, Paktia, and Nangarhar provinces reportedly held meetings with tribal elders and influential figures to encourage participation in protests against Pakistan. Some tribal elders described the outreach as unusual, saying they had not been invited to official meetings since the Taliban returned to power. Taliban officials in Kabul were also said to have asked former Afghan government officials and former members of the House of Representatives to publicly support the Taliban in its war with Pakistan. Former Afghan soldiers in Paktika and Khost provinces also state that the Taliban were seeking out and forcibly taking ex-soldiers, particularly those trained to operate heavy weapons such as mortars and artillery, to border areas to assist in the conflict. Afghan news outlet reported that Taliban forces people in Badakhshan province to raise anti-Pakistan slogans.
Sources: en.wikipedia.org
It binds to and activates PPAR delta, a nuclear receptor that controls expression of genes related to fatty acid oxidation. This mechanism can alter energy metabolism in animal models. It is not a direct stimulant or fat-burning enzyme.
Early-stage trials examined lipid and glucose markers, but the development program was discontinued. Published human results are limited and do not support approved use for any indication. Claims of performance or health benefits remain unproven.
Yes. Laboratories use LC-MS/MS to detect GW501516 and its metabolites in urine. Detection depends on timing and sensitivity, but the substance is banned at all times.
It targets PPARδ, a nuclear receptor involved in lipid and energy metabolism. It does not act primarily on androgen receptors. This distinction separates it from SARMs.